Export 12 results:
[ Author(Desc)] Title Type Year
Filters: Author is Scott, Ingrid U  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Chan, C. K., Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial., JAMA Ophthalmol, 2019.
I. U. Scott, VanVeldhuisen, P. C., Barton, F., Oden, N. L., Ip, M. S., Blodi, B. A., Worrall, M., and Fish, G. E., Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial., JAMA Ophthalmol, 2019.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Altaweel, M., and Berinstein, D. M., Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial., JAMA Ophthalmol, vol. 136, no. 4, pp. 337-345, 2018.
I. U. Scott, Figueroa, M. J., Oden, N. L., Ip, M. S., Blodi, B. A., and VanVeldhuisen, P. C., SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion., Am J Ophthalmol, vol. 184, pp. 147-156, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Awh, C. C., Kunimoto, D. Y., Marcus, D. M., Wroblewski, J. J., and King, J., Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial., JAMA, vol. 317, no. 20, pp. 2072-2087, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., King, J., Antoszyk, A. N., Peters, M. A., and Tolentino, M., Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4., JAMA Ophthalmol, vol. 135, no. 6, pp. 639-649, 2017.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., Hartnett, M. Elizabeth, and Cohen, G., Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10., Ophthalmology, vol. 118, no. 2, pp. 345-52, 2011.
I. U. Scott, Blodi, B. A., Ip, M. S., VanVeldhuisen, P. C., Oden, N. L., Chan, C. K., and Gonzalez, V., SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type., Ophthalmology, vol. 116, no. 4, pp. 756-61, 2009.
I. U. Scott, VanVeldhuisen, P. C., Oden, N. L., Ip, M. S., Blodi, B. A., J Jumper, M., and Figueroa, M., SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion., Ophthalmology, vol. 116, no. 3, pp. 504-12, 2009.
I. U. Scott, Oden, N. L., VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., and Antoszyk, A. N., SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design., Am J Ophthalmol, vol. 148, no. 5, pp. 725-732.e7, 2009.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., SCORE2 Report 2: Study Design and Baseline Characteristics., Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.
I. U. Scott, VanVeldhuisen, P. C., Ip, M. S., Blodi, B. A., Oden, N. L., Figueroa, M., and Dugel, P. U., SCORE2 Report 2: Study Design and Baseline Characteristics., Ophthalmology, vol. 124, no. 2, pp. 245-256, 2017.